Payment overview · 2025
General Payments
$2,773.73
124 reported records · 27 companies
Healthcare provider profile · identity verified
Muhammad Naeem, MD
Allopathic & Osteopathic Physicians|Internal Medicine · YONKERS, NY · NPI 1568431179
Verified facts
What the public records show
CMS Open Payments records show Muhammad Naeem, MD received $2,773.73 in general payments during 2025 across 124 reported records.
Novo Nordisk Inc accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ibsrela, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 302 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ibsrela by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 302 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 489 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $408.02 | 14.7% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $392.74 | 14.2% | 25 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $194.80 | 7.0% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $153.91 | 5.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $152.18 | 5.5% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $142.01 | 5.1% | 6 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $135.00 | 4.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $130.86 | 4.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $117.17 | 4.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $110.74 | 4.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $101.30 | 3.6% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $98.02 | 3.5% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $84.65 | 3.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.58 | 2.5% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $69.51 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $55.56 | 2.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.10 | 1.9% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $53.19 | 1.9% | 3 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $50.53 | 1.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.27 | 1.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $27.82 | 1.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.70 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.67 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.13 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.52 | 0.7% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.49 | 0.7% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.26 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,773.73 | 124 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $408.02 | 18 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $408.02 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $263.58 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $221.78 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $196.11 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $194.80 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $141.27 | 11 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $130.86 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $124.47 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $113.20 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $110.74 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $101.30 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $84.65 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.05 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $77.18 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $72.07 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.58 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.58 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $69.51 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $64.84 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $55.56 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $55.22 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $53.19 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.33 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $12.64 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $12.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 101 | exact normalized | Medicare Part D |
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 302 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 89 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 186 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 102 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 213 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
302 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
185 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
213 | 38 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
302 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
237 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
122 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
102 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
106 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
186 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
102 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
489 | 73 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
101 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1221 | 221 |
| Amlodipine Besylate | Amlodipine Besylate | 1008 | 180 |
| Metformin Hcl | Metformin Hcl | 825 | 138 |
| Metoprolol Succinate | Metoprolol Succinate | 780 | 133 |
| Tamsulosin Hcl | Tamsulosin Hcl | 610 | 111 |
| Omeprazole | Omeprazole | 583 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 530 | 86 |
| Gabapentin | Gabapentin | 528 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 521 | 98 |
| Losartan Potassium | Losartan Potassium | 498 | 95 |
| Eliquis | Apixaban | 489 | 73 |
| Celecoxib | Celecoxib | 484 | 149 |
| Januvia | Sitagliptin Phosphate | 484 | 65 |
| Furosemide | Furosemide | 442 | 88 |
| Lisinopril | Lisinopril | 400 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 364 | 84 |
| Linzess | Linaclotide | 302 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 297 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 294 | 52 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 294 | 43 |
| Famotidine | Famotidine | 277 | 43 |
| Glimepiride | Glimepiride | 275 | 41 |
| Simvastatin | Simvastatin | 272 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 253 | 44 |
| Azithromycin | Azithromycin | 249 | 183 |
| Fluticasone Propionate | Fluticasone Propionate | 248 | 63 |
| Sertraline Hcl | Sertraline Hcl | 243 | 31 |
| Jardiance | Empagliflozin | 237 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 227 | 74 |
| Carvedilol | Carvedilol | 223 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 213 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 201 | 59 |
| Mirtazapine | Mirtazapine | 201 | 28 |
| Tradjenta | Linagliptin | 193 | 21 |
| Ozempic | Semaglutide | 186 | 27 |
| Myrbetriq | Mirabegron | 185 | 22 |
| Xiidra | Lifitegrast | 185 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 182 | 40 |
| Finasteride | Finasteride | 177 | 26 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 169 | 24 |
| Vascepa | Icosapent Ethyl | 166 | 19 |
| Valsartan | Valsartan | 165 | 31 |
| Sucralfate | Sucralfate | 158 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 156 | 27 |
| Donepezil Hcl | Donepezil Hcl | 149 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 33 |
| Methylprednisolone | Methylprednisolone | 143 | 110 |
| Ibuprofen | Ibuprofen | 142 | 42 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 138 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 138 | 33 |
| Divalproex Sodium | Divalproex Sodium | 134 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 26 |
| Cefuroxime | Cefuroxime Axetil | 132 | 102 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 130 | 12 |
| Montelukast Sodium | Montelukast Sodium | 129 | 22 |
| Prednisone | Prednisone | 126 | 50 |
| Xarelto | Rivaroxaban | 123 | 19 |
| Trulicity | Dulaglutide | 122 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 119 | 40 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 117 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 25 |
| Levetiracetam | Levetiracetam | 114 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 30 |
| Clonazepam | Clonazepam | 108 | 20 |
| Entresto | Sacubitril/Valsartan | 106 | 19 |
| Labetalol Hcl | Labetalol Hcl | 105 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 22 |
| Atenolol | Atenolol | 102 | 19 |
| Rexulti | Brexpiprazole | 102 | 11 |
| Gemtesa | Vibegron | 101 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 19 |
| Ezetimibe | Ezetimibe | 100 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 96 | 15 |
| Chlorthalidone | Chlorthalidone | 96 | 16 |
| Buspirone Hcl | Buspirone Hcl | 95 | 14 |
| Edarbi | Azilsartan Medoxomil | 95 | suppressed |
| Mounjaro | Tirzepatide | 89 | 16 |
| Colchicine | Colchicine | 88 | 24 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 88 | 17 |
| Baclofen | Baclofen | 87 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 87 | 28 |
| Sumatriptan | Sumatriptan | 86 | suppressed |
| Potassium Chloride | Potassium Chloride | 85 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 84 | 20 |
| Spironolactone | Spironolactone | 83 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 13 |
| Alcohol Swab | Alcohol Antiseptic Pads | 80 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 80 | 17 |
| Tramadol Hcl | Tramadol Hcl | 80 | 27 |
| Glipizide Er | Glipizide | 79 | 18 |
| Nifedipine Er | Nifedipine | 78 | 21 |
| Lorazepam | Lorazepam | 75 | 22 |
| Novolog Flexpen | Insulin Aspart | 72 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 21 |
| Allopurinol | Allopurinol | 68 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 65 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 65 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 12 |
| Trazodone Hcl | Trazodone Hcl | 64 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 63 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 12 |
| Bupropion Xl | Bupropion Hcl | 61 | suppressed |
| Naproxen | Naproxen | 61 | 17 |
| Rybelsus | Semaglutide | 61 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 46 |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 59 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 59 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 16 |
| Torsemide | Torsemide | 59 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 56 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Restasis | Cyclosporine | 56 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 55 | 11 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Glipizide | Glipizide | 54 | suppressed |
| Brilinta | Ticagrelor | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Ramipril | Ramipril | 51 | 11 |
| Ssd | Silver Sulfadiazine | 50 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 48 | 44 |
| Silver Sulfadiazine | Silver Sulfadiazine | 48 | 20 |
| Synthroid | Levothyroxine Sodium | 48 | 14 |
| Bystolic | Nebivolol Hcl | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | suppressed |
| Pregabalin | Pregabalin | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 45 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 44 | 25 |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 42 | 14 |
| Hydrocortisone | Hydrocortisone | 42 | 20 |
| Latanoprost | Latanoprost | 41 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 41 | suppressed |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 16 |
| Nystatin | Nystatin | 38 | 17 |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 23 |
| Alogliptin | Alogliptin Benzoate | 34 | 14 |
| Digoxin | Digoxin | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 34 | 14 |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 32 | 24 |
| Valproic Acid | Valproic Acid | 32 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | 12 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Livalo | Pitavastatin Calcium | 31 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 31 | 14 |
| Valacyclovir | Valacyclovir Hcl | 31 | 21 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 30 | 30 |
| Lokelma | Sodium Zirconium Cyclosilicate | 30 | suppressed |
| Niacin | Niacin | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | 18 |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Dexilant | Dexlansoprazole | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | 13 |
| Pimecrolimus | Pimecrolimus | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 19 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 27 | 20 |
| Haloperidol | Haloperidol | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 26 | suppressed |
| Epinephrine | Epinephrine | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | 13 |
| Ondansetron Odt | Ondansetron | 25 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Azathioprine | Azathioprine | 24 | suppressed |
| Calcium Acetate | Calcium Acetate | 24 | suppressed |
| Ergotamine-Caffeine | Ergotamine Tartrate/Caffeine | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 23 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Zerviate | Cetirizine Hcl | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 11 |
| Dextrose In Water | Dextrose 5 % In Water | 21 | 15 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fycompa | Perampanel | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 14 |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Daptomycin | Daptomycin | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Procrit | Epoetin Alfa | 19 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Entacapone | Entacapone | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Bepreve | Bepotastine Besilate | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Mitigare | Colchicine | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lotemax | Loteprednol Etabonate | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Ibsrela | Tenapanor Hcl | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Webcol | Alcohol Antiseptic Pads | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Glumetza | Metformin Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lovaza | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,773.73 · 124 records | Novo Nordisk Inc | AREXVY, BREZTRI, CAPLYTA, CONTRAVE, CREXONT, Cologuard Collection Kit, DUPIXENT, FARXIGA, GEMTESA, IBSRELA, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, RECORLEV, RELISTOR, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND, ZORYVE, ZTLido | 27 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error